Showing 4511-4520 of 7240 results for "".
- Health Canada Approves BMS' Yervoy for Melanomahttps://practicaldermatology.com/news/20120208-health_canada_approves_bms_yervoy_for_melanoma/2459869/Health Canada approved Yervoy (ipilimumab 3mg/kg, Bristol-Myers Squibb) for the treatment of unresectable or metastatic melanoma in patients who have failed or do not tolerate other systemic therapy for advanced diseas
- CLL Linked to Higher Skin Cancer Risk and Worse Outcomes in Nationwide Studyhttps://practicaldermatology.com/news/cll-linked-to-higher-skin-cancer-risk-and-worse-outcomes-in-nationwide-study/2486526/Patients with chronic lymphocytic leukemia (CLL) face a significantly elevated risk of developing skin cancer, according to a nationwide Danish cohort study spanning three decades. Study investigators analyzed registry data fr
- Phase 3 Data Highlight Early and Broad Response With Deuruxolitinibhttps://practicaldermatology.com/news/phase-3-data-highlight-early-and-broad-response-with-deuruxolitinib/2486483/Two posters presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting provide complementary Phase 3 evidence supporting the efficacy of deuruxolitinib, an oral Janus kinase (JAK)1/JAK2 inhibitor, in adults with severe alopecia areata (AA). Both analyses pooled data from th
- Rademikibart Shows High Long-Term Efficacy in Atopic Dermatitishttps://practicaldermatology.com/news/rademikibart-shows-high-long-term-efficacy-in-atopic-dermatitis/2486495/Rademikibart, a next-generation anti–IL-4 receptor alpha monoclonal antibody, demonstrated robust and sustained efficacy in moderate-to-severe atopic dermatitis (AD) through 52 weeks, according to Phase 3 RADIANT-AD data presented by Cheng Zhou, MD, at the American Academy of Dermatology (AAD) 20
- GPX4 Modulator Shows Early Promise in First-in-Human Studyhttps://practicaldermatology.com/news/gpx4-modulator-shows-early-promise-in-first-in-human-study/2486474/A novel topical therapy targeting cellular senescence showed early biologic activity across multiple dermatologic conditions in a Phase 1 clinical trial, according to data presented by Frederick Beddingfield III, MD, PhD, FAAD, at the Dermatology Innovation Forum during the American Academy of De
- Upadacitinib Shows Strong Hair Regrowth in Alopecia Areatahttps://practicaldermatology.com/news/upadacitinib-shows-strong-hair-regrowth-in-alopecia-areata/2486456/Upadacitinib demonstrated robust efficacy in both adolescents and adults with severe alopecia areata (AA), with particularly strong responses observed in younger patients, according to a subgroup analysis of two Phase 3 trials presented by Melinda Gooderham, MD, MSc, at the American Academy of De
- Commentary: Is the IMQ Mouse Model Hindering Psoriasis Research?https://practicaldermatology.com/news/commentary-is-the-imq-mouse-model-hindering-psoriasis-research/2485698/A perspective piece in the Journal of Investigative Dermatology takes a criticial look at the imiquimod (IMQ) mouse model, suggesting its unversality and commonality may be impeding translational progress in psoriasis resea
- Aesthetic Sequelae of GLP-1 Receptor Agonists Highlighted in Clinical Reviewhttps://practicaldermatology.com/news/aesthetic-sequelae-of-glp-1-receptor-agonists-highlighted-in-clinical-review/2485615/Dermatologists are increasingly encountering aesthetic complications associated with GLP-1 receptor agonist (RA)–induced weight loss, according to a clinical review presented at the South Beach Symposium. The poster, b
- Analysis: Ustekinumab, IL-23 Inhibitors Show Higher Drug Survival in Psoriasishttps://practicaldermatology.com/news/analysis-ustekinumab-il-23-inhibitors-show-higher-drug-survival-in-psoriasis/2485295/A new Danish cohort study using data from the DERMBIO registry suggests ustekinumab was linked with the best 5-year survival of comparators in bionaive patients with psoriasis. The analysis included a total of 7,193 treatment
- Acne Incidence Higher with Higher-Dose LNG-IUS, Meta-Analysis Findshttps://practicaldermatology.com/news/acne-incidence-higher-with-higher-dose-lng-ius-meta-analysis-finds/2485045/A new systematic review and meta-analysis shows the incidence of acne among users of the levonorgestrel-releasing intrauterine system (LNG-IUS), identifying both dosage and age as influential factors. The review included nine ra